spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  calcitonin 

 HSMN NewsFeed - 25 Jun 2025
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 4 Dec 2024
Study published in the New England Journal of Medicine AI Concludes that the Sepsis ImmunoScore(TM), the First FDA-Authorized AI Tool for Sepsis, has both significant Diagnostic and Predictive Power
Diagnostics
 HSMN NewsFeed - 16 Nov 2023
Ad Astra Diagnostics receives 510(k) clearance of QScout(TM) hematology analyzer, the first to report measures of infection and severity at point-of-care
Diagnostics FDA
 HSMN NewsFeed - 17 Aug 2023
AbbVie Announces European Commission Approval of AQUIPTA(R) (atogepant) for the Preventive Treatment of Migraine in Adults
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 21 Apr 2023
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA(R)) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Feb 2022
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 14 Feb 2022
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Nov 2021
NURTEC(R) ODT Approved In Kuwait For Acute Treatment Of Migraine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Oct 2020
Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 May 2020
Emgality(R) Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Mar 2020
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 28 Jan 2020
Beckman Coulter's Access PCT Procalcitonin Assay Receives U.S. FDA 510(k) Clearance
Devices Diagnostics FDA
 HSMN NewsFeed - 18 Dec 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality(R) (galcanezumab-gnlm)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Aug 2019
Lilly Announces Positive Results for Emgality(R) (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Jul 2019
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality(R) (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jul 2019
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality(R) (galcanezumab-gnlm) in Episodic Cluster Headache
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Mar 2019
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Dec 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Nov 2018
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality(TM) (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 21 Sep 2018
Lilly Receives Positive CHMP Opinion for Emgality(TM) (galcanezumab) for the Prophylaxis of Migraine in Adults
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 12 Sep 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 28 Jun 2018
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 18 May 2018
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Biopharmaceuticals Devices Drug Delivery FDA
 HSMN NewsFeed - 15 May 2018
Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Apr 2018
AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
Biopharmaceuticals Endocrinology Product Launch
 HSMN NewsFeed - 11 Dec 2017
FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2017
Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Sep 2017
IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine
Biopharmaceutical Neurology
 HSMN NewsFeed - 4 Aug 2017
Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Jun 2017
Lilly Announces Strategic Collaboration with KeyBioscience AG
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 18 May 2017
Amgen Submits Biologics License Application To The FDA For Erenumab
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 May 2017
Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Mar 2016
Roche Submits Filing to FDA For cobas(R) Procalcitonin (Pct) Assay to Help Clinicians Assess Response of Septic Patients to Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Feb 2016
Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Aug 2015
Alder BioPharmaceuticals Appoints Paul B. Cleveland to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jul 2015
Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program
Biopharmaceuticals Acquisitions Licensing
 HSMN NewsFeed - 13 Aug 2014
Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA
 HSMN NewsFeed - 13 Jan 2014
Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 18 Mar 2013
Labrys Biologics Announces Key Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2013
Amgen Outlines Long-Term Strategy
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2010
Unigene Names Alex Martin VP Business Development and Head of Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2010
Emisphere Provides an Update on Osteoarthritis Phase III Study With Oral Calcitonin
Biopharmaceuticals
 HSMN NewsFeed - 22 Jul 2010
Tarsa Therapeutics Advances Phase III ORACAL Trial of its Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2010
Unigene Appoints New CEO, Ashleigh Palmer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2010
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 9 Jun 2009
Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 7 Apr 2008
BRAHMS Receives FDA Clearance to Market Automated Procalcitonin (PCT) Test
Diagnostics FDA
 HSMN NewsFeed - 15 Nov 2007
Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Oct 2007
FDA Clears bioMerieux's VIDAS(R) B.R.A.H.M.S PCT(R) Assay
Diagnostics FDA
 HSMN NewsFeed - 17 Aug 2007
Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 1 Aug 2007
Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 12 Jun 2007
Emisphere Technologies, Inc. Appoints Laura Kragie as Vice President of Clinical Development/Chief Medical Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 10 Apr 2007
Emisphere Technologies, Inc. Appoints Michael V. Novinski as President and Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 27 Feb 2007
Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 16 Jan 2007
Emisphere Announces Executive Management Changes
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 13 Jul 2006
Nastech Pharmaceutical Company Receives FDA Communication Concerning Calcitonin-Salmon Nasal Spray
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 10 May 2006
Unigene Enters into Exclusive Distribution Agreement for Fortical(R) Nasal Spray in Israel
Biopharmaceuticals Drug Delivery Distribution
Return to NewsFeed  

 Additional items found! 25

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 25 additional stories matching:
calcitonin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.